GlassScriptPhysician profile
Svitlana Crawley
NPI 1568897841
$3,817.84
in general payments reported to CMS, 2019-2025
34 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $939 · 2023: $1,299 · 2024: $146 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,859 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,859.03 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $811.05 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $325.30 | 2022-2023 | Farxiga |
| Amgen INC. | $302.31 | 2022-2023 | Repatha, Prolia, Evenity |
| Teva Pharmaceuticals USA, INC. | $277.07 | 2025 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $208.30 | 2025 | Fanapt |
| Alkermes, INC. | $194.34 | 2025 | Lybalvi, Aristada, Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $144.66 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $137.44 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $134.09 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.53 | 2023-2025 | Caplyta |
| Organogenesis INC. | $124.52 | 2022 | |
| Idorsia Pharmaceuticals US INC | $120.89 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $77.16 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $68.80 | 2022 | |
| Lundbeck LLC | $66.98 | 2025 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $64.55 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.36 | 2022-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.95 | 2022 | |
| Nestle Healthcare Nutrition INC. | $54.45 | 2022-2023 | |
| Radius Health, INC. | $53.75 | 2022-2023 | Tymlos |
| Biohaven Pharmaceutical Holding Company LTD. | $47.09 | 2022 | |
| Ironshore Pharmaceuticals INC. | $42.40 | 2024 | |
| Vertical Pharmaceuticals, LLC | $40.05 | 2025 | Relexxii |
| Esperion Therapeutics, INC. | $39.38 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.93 | 2025 | Cobenfy |
| Glaxosmithkline, LLC. | $27.03 | 2023 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $21.91 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $21.90 | 2023 | Xarelto |
| Pfizer INC. | $20.46 | 2023 | |
| Corium, LLC | $20.40 | 2025 | Azstarys |
| Lilly USA, LLC | $20.13 | 2023 | Jardiance, Emgality |
| Mannkind Corporation | $20.00 | 2023 | Afrezza |
| Sanofi Pasteur INC. | $18.52 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Svitlana Crawley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.